Rhonda Szczesniak1, Sonya L Heltshe2, Sanja Stanojevic3, Nicole Mayer-Hamblett4. 1. Division of Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. Electronic address: Rhonda.Szczesniak@cchmc.org. 2. Department of Pediatrics, University of Washington, Seattle, WA, USA; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA. 3. Division of Respiratory Medicine, Hospital for Sick Children, Toronto, ON, Canada. 4. Department of Pediatrics, University of Washington, Seattle, WA, USA; Cystic Fibrosis Foundation Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Forced expiratory volume in 1s (FEV1) is an established marker of cystic fibrosis (CF) disease progression that is used to capture clinical course and evaluate therapeutic efficacy. The research community has established FEV1 surveillance data through a variety of observational data sources such as patient registries, and there is a growing pipeline of new CF therapies demonstrated to be efficacious in clinical trials by establishing improvements in FEV1. RESULTS: In this review, we summarize from a statistical perspective the clinical relevance of FEV1 based on its association with morbidity and mortality in CF, its role in epidemiologic studies of disease progression and comparative effectiveness, and its utility in clinical trials. In addition, we identify opportunities to advance epidemiologic research and the clinical development pipeline through further statistical considerations. CONCLUSIONS: Our understanding of CF disease course, therapeutics, and clinical care has evolved immensely in the past decades, in large part due to the thoughtful application of rigorous research methods and meaningful clinical endpoints such as FEV1. A continued commitment to conduct research that minimizes the potential for bias, maximizes the limited patient population, and harmonizes approaches to FEV1 analysis while maintaining clinical relevance, will facilitate further opportunities to advance CF care.
BACKGROUND: Forced expiratory volume in 1s (FEV1) is an established marker of cystic fibrosis (CF) disease progression that is used to capture clinical course and evaluate therapeutic efficacy. The research community has established FEV1 surveillance data through a variety of observational data sources such as patient registries, and there is a growing pipeline of new CF therapies demonstrated to be efficacious in clinical trials by establishing improvements in FEV1. RESULTS: In this review, we summarize from a statistical perspective the clinical relevance of FEV1 based on its association with morbidity and mortality in CF, its role in epidemiologic studies of disease progression and comparative effectiveness, and its utility in clinical trials. In addition, we identify opportunities to advance epidemiologic research and the clinical development pipeline through further statistical considerations. CONCLUSIONS: Our understanding of CF disease course, therapeutics, and clinical care has evolved immensely in the past decades, in large part due to the thoughtful application of rigorous research methods and meaningful clinical endpoints such as FEV1. A continued commitment to conduct research that minimizes the potential for bias, maximizes the limited patient population, and harmonizes approaches to FEV1 analysis while maintaining clinical relevance, will facilitate further opportunities to advance CF care.
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Julia Emerson; Christopher H Goss; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: W J Morgan; S M Butler; C A Johnson; A A Colin; S C FitzSimmons; D E Geller; M W Konstan; M J Light; H R Rabin; W E Regelmann; D V Schidlow; D C Stokes; M E Wohl; H Kaplowitz; M M Wyatt; S Stryker Journal: Pediatr Pulmonol Date: 1999-10
Authors: Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Michal Kulich; Margaret Rosenfeld; Jonathan Campbell; Richard Kronmal; Ron L Gibson; Christopher H Goss; Bonnie Ramsey Journal: Am J Respir Crit Care Med Date: 2005-06-23 Impact factor: 21.405
Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Sonya L Heltshe; Steven M Rowe; Michelle Skalland; Arthur Baines; Manu Jain Journal: Am J Respir Crit Care Med Date: 2018-06-01 Impact factor: 21.405
Authors: A K M Ashiqul Haque; Alexander Dewerth; Justin S Antony; Joachim Riethmüller; Georg R Schweizer; Petra Weinmann; Ngadhnjim Latifi; Hanzey Yasar; Nicoletta Pedemonte; Elvira Sondo; Brian Weidensee; Anjali Ralhan; Julie Laval; Patrick Schlegel; Christian Seitz; Brigitta Loretz; Claus-Michael Lehr; Rupert Handgretinger; Michael S D Kormann Journal: Sci Rep Date: 2018-11-13 Impact factor: 4.379
Authors: Kelsey Nusbaum; Stephanie S Filigno; Julie Feldstein; Elizabeth Hente; Elizabeth Koch; Lisa Mullen; Jeanne Weiland; Thomas Boat; Christopher Siracusa Journal: Pediatr Pulmonol Date: 2020-02-10
Authors: Michael J Bozzella; Hollis Chaney; Iman Sami; Anastassios Koumbourlis; James E Bost; Edith T Zemanick; Robert J Freishtat; Keith A Crandall; Andrea Hahn Journal: Pediatr Infect Dis J Date: 2021-11-01 Impact factor: 3.806